sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Edoxaban

Medicine

Edoxaban

SAVAYSA is a factor Xa inhibitor

Medication guideLabel updated 2025-07-10

Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗

Boxed warning

WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning. (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN: SAVAYSA should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used. (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS: Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If SAVAYSA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance. (C) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with SAVAYSA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. A. REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN SAVAYSA should not be used in patients with CrCL > 95 mL/min. B. PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. C. SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with SAVAYSA who are receiving neuraxial anesthesia or undergoing spinal puncture. Consider these risks when scheduling pa

Drug facts

Used for
  • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) SAVAYSA is indicated
  • for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated
  • to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin . 1.2 Treatment of Deep Vein Thrombosis and Pulmonary Embolism SAVAYSA is indicated
How to take it
Take SAVAYSA exactly as prescribed by your healthcare provider.

What it is used for

SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant 1.1 Reduction in the Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).

Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin. 1.2 Treatment of Deep Vein Thrombosis and Pulmonary Embolism SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.

The most important thing to know

For people who take SAVAYSA for nonvalvular atrial fibrillation (a type of irregular heartbeat): People with nonvalvular atrial fibrillation are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. SAVAYSA reduces your risk of having a stroke by helping to prevent clots from forming.

Your healthcare provider should check your kidney function before you start taking SAVAYSA. People whose kidneys work really well should not receive SAVAYSA because it may not work well to prevent stroke. Do not stop taking SAVAYSA without first talking to the healthcare provider who prescribed it for you. Stopping SAVAYSA increases your risk of having a stroke.

SAVAYSA can cause bleeding which can be serious, and sometimes lead to death. This is because SAVAYSA is a blood thinner medicine that reduces blood clotting. During treatment with SAVAYSA, you may bleed more easily, bleed longer, or bruise more easily. Call your healthcare provider or get medical help right away if you experience bleeding that is severe (for example, coughing up or vomiting blood) or bleeding that cannot be controlled.

You may have a higher risk of bleeding if you take SAVAYSA and take other medicines that increase your risk of bleeding, including: aspirin or aspirin-containing products long-term (chronic) use of nonsteroidal anti-inflammatory drugs (NSAIDs) long-term (chronic) use of blood thinner medicines, such as: warfarin sodium (Coumadin, Jantoven) any medicine that contains heparin selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) other medicines to prevent or treat blood clots Tell your healthcare provider if you take any of these medicines.

Ask your healthcare provider or pharmacist if you are not sure if your medicine is one listed above. Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like SAVAYSA, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis).

Your risk of developing a spinal or epidural blood clot is higher if: a thin tube called an epidural catheter is placed in your back to give you certain medicine you take NSAIDs or a medicine to prevent blood from clotting you have a history of difficult or repeated epidural or spinal punctures you have a history of problems with your spine or have had surgery on your spine.

If you take SAVAYSA and receive spinal anesthesia or have a spinal puncture, your healthcare provider should watch you closely for symptoms of spinal or epidural blood clots. Tell your healthcare provider right away if you have back pain, tingling, numbness (especially in your legs and feet), muscle weakness, or loss of control of the bowels or bladder (incontinence).

SAVAYSA is not for people with mechanical heart valves or people who have moderate to severe narrowing (stenosis) of their mitral valve. SAVAYSA is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing, who have a history of blood clots. See "

How to take it

Take SAVAYSA exactly as prescribed by your healthcare provider. Your healthcare provider will decide how long you should take SAVAYSA. Do not change your dose or stop taking SAVAYSA unless your healthcare provider tells you to. If you are taking SAVAYSA for nonvalvular atrial fibrillation, stopping SAVAYSA may increase your risk of having a stroke.

Take SAVAYSA with or without food. If you have difficulty swallowing the tablet whole, talk to your healthcare provider about other ways to take SAVAYSA. If you miss a dose of SAVAYSA, take it as soon as you remember on the same day. Take your next dose at your usual time the next day. Do not take more than one dose of SAVAYSA at the same time to make up for a missed dose.

Do not run out of SAVAYSA. Refill your prescription before you run out. If you take too much SAVAYSA, go to the nearest hospital emergency room or call your healthcare provider right away. Call your healthcare provider right away if you fall or injure yourself, especially if you hit your head. Your healthcare provider may need to check you.

What are the possible side effects of SAVAYSA? SAVAYSA can cause serious side effects. The most common side effects in people who take SAVAYSA for nonvalvular atrial fibrillation include bleeding and low red blood cell count (anemia). The most common side effects in people who take SAVAYSA for deep vein thrombosis and pulmonary embolism include bleeding, rash, abnormal liver function tests, and low red blood cell count (anemia).

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects, and when to stop

" for more information about side effects. What is SAVAYSA? SAVAYSA is a prescription medicine used to: reduce the risk of stroke and blood clots in people who have atrial fibrillation not caused by a heart valve problem (nonvalvular atrial fibrillation). treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism), after you have been treated with an injectable blood thinner medicine for 5 to 10 days.

It is not known if SAVAYSA is safe and effective in children with known deep vein thrombosis or pulmonary embolism.

Who should not take it

Do not take SAVAYSA if you currently have certain types of abnormal bleeding. Before taking SAVAYSA, tell your healthcare provider about all of your medical conditions, including if you: have liver or kidney problems have ever had bleeding problems have a mechanical heart valve have antiphospholipid syndrome have cancer of the stomach or intestine (gastrointestinal cancer) are pregnant or plan to become pregnant.

It is not known if SAVAYSA will harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with SAVAYSA. Females who are able to become pregnant: Talk with your healthcare provider about pregnancy planning during treatment with SAVAYSA. Talk with your healthcare provider about your risk for severe uterine bleeding if you are treated with blood thinner medicines, including SAVAYSA.

are breastfeeding or plan to breastfeed. It is not known if SAVAYSA passes into your breast milk. Do not breastfeed during treatment with SAVAYSA. Tell all of your healthcare providers and dentists that you are taking SAVAYSA. They should talk to the healthcare provider who prescribed SAVAYSA for you, before you have any surgery, medical or dental procedure.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way SAVAYSA works. Certain medicines may increase your risk of bleeding or stroke when taken with SAVAYSA. Know the medicines you take.

Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Storing it

Store SAVAYSA at room temperature between 68°F to 77°F (20°C to 25°C). Keep SAVAYSA and all medicines out of the reach of children.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Edoxaban; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/edoxaban

APA 7th

sofidex. (2026, August 2). Edoxaban. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/edoxaban

AMA 11th

Edoxaban. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/edoxaban

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.